Sage Therapeutics scraps plans for Parkinson’s drug after mid-stage failure
Sage Therapeutics said on Wednesday it would stop working on its experimental drug for Parkinson’s disease after the treatment failed a mid-stage study, sending the company’s shares to a record low in morning trading.